Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer

BackgroundDuring the course of radiation treatment for prostate cancer, patients may have unintentional interruptions in their treatment course due to a wide variety of factors. Stereotactic body radiation therapy (SBRT) decreases the number of treatments compared to conventionally fractionated radi...

Full description

Bibliographic Details
Main Authors:	Abigail N. Pepin, Alan Zwart, Malika Danner, Marylin Ayoob, Thomas Yung, Brian T. Collins, Deepak Kumar, Simeng Suy, Nima Aghdam, Sean P. Collins
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Oncology
Subjects:	SBRT (stereotactic body radiation therapy) prostate cancer treatment interruption Treatment delay treatment noncompletion
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.796496/full

Similar Items

Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes
by: Michael Carrasquilla, et al.
Published: (2023-11-01)

Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer
by: Tamir N. Sholklapper, et al.
Published: (2022-03-01)

Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity
by: Marcin Miszczyk, et al.
Published: (2023-02-01)

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
by: Nima Aghdam, et al.
Published: (2020-01-01)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer
by: Antonin Levy, et al.
Published: (2023-07-01)

Stereotactic lung reirradiation for local relapse: A case series
by: Rémy Kinj, et al.
Published: (2021-05-01)

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
by: Abigail Pepin, et al.
Published: (2021-09-01)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
by: Nima Aghdam, et al.
Published: (2020-07-01)

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
by: Lindsey Gallagher, et al.
Published: (2023-10-01)

Developments in Stereotactic Body Radiotherapy
by: Anoop Haridass
Published: (2018-12-01)

Stereotactic radiotherapy: An educational narrative review
by: Agha Muhammad Hammad Khan, et al.
Published: (2024-03-01)

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
by: Sarthak Shah, et al.
Published: (2021-11-01)

Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer
by: Rishabh K. Simhal, et al.
Published: (2022-12-01)

A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?
by: Faiez Al-Shafa, et al.
Published: (2019-06-01)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
by: Einsley-Marie eJanowski, et al.
Published: (2015-07-01)

Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy
by: E. Leung, et al.
Published: (2020-01-01)

Evolution of Stereotactic Ablative Radiotherapy in Lung Cancer and Birmingham’s (UK) Experience
by: Sundus Yahya, et al.
Published: (2018-07-01)

Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases
by: Sara Lindberg, et al.
Published: (2022-09-01)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
by: Abigail Pepin, et al.
Published: (2020-05-01)

A feasibility study of stereotactic radiosurgery/stereotactic body radiotherapy/stereotactic ablative radiotherapy practice using tomoedge in helical tomotherapy for lung, liver, and spine targets
by: N V. N. Madhusudhana Sresty, et al.
Published: (2021-01-01)

Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma
by: Eleni Gkika, et al.
Published: (2017-11-01)

Stereotactic body radiotherapy for osseous low alpha–beta resistant metastases for pain relief—SOLAR-P
by: Eric K. Nguyen, et al.
Published: (2021-09-01)

Stereotactic ablative radiotherapy for primary renal cell carcinoma
by: Daniel X. Yang, et al.
Published: (2024-01-01)

Adrenal oligometastasis cured with stereotactic ablative radiotherapy
by: Julia Malone, BSC, et al.
Published: (2020-11-01)

Application of stereotactic body radiotherapy in advanced pancreatic cancers in Australia
by: Laurence Kim, et al.
Published: (2019-03-01)

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy
by: Michael Carrasquilla, et al.
Published: (2021-01-01)

Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol
by: Wei Liu, et al.
Published: (2022-04-01)

Determinants of treatment interruption and outcome among smear-positive pulmonary tuberculosis patients in a tuberculosis unit of Purba Bardhaman district of West Bengal
by: Chinmay Nandi, et al.
Published: (2022-01-01)

Effect of treatment interruptions and outcomes in cancer patients undergoing radiotherapy during the first wave of COVID-19 pandemic in a tertiary care institute
by: Sandip Kumar Barik, et al.
Published: (2022-07-01)

Compensability index for compensation radiotherapy after treatment interruptions
by: Putora Paul, et al.
Published: (2012-12-01)

Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma
by: Eleni Gkika, et al.
Published: (2017-07-01)

First UK patient cohort treated with stereotactic ablative radiotherapy for primary kidney cancer
by: Anjali Zarkar, et al.
Published: (2023-07-01)

Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer
by: Kevin T. Tran, et al.
Published: (2023-03-01)

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma
by: Rohit K. Raj, et al.
Published: (2023-12-01)

Dosimetric Benefit of Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Metastases
by: Fabian Weykamp, et al.
Published: (2022-12-01)

Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancer
by: Michael C. Repka, et al.
Published: (2024-03-01)

Dosimetric comparison of different treatment modalities for stereotactic radiotherapy
by: Shih-Ming Hsu, et al.
Published: (2017-09-01)

Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer
by: Mix M, et al.
Published: (2019-12-01)

Impact of neoadjuvant relugolix on patient-reported sexual function and bother
by: Jessica Y. Hsueh, et al.
Published: (2024-04-01)

Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy
by: Yanhao Liu, et al.
Published: (2021-12-01)